Levomepromazine (methotrimeprazine) and the last 48 hours
Title
Levomepromazine (methotrimeprazine) and the last 48 hours
Creator
O'Neill J; Fountain A
Identifier
Publisher
Hospital Medicine
Date
1999
Subject
Humans; Terminal Care; Non-U.S. Gov't; Research Support; Terminally Ill/psychology; Psychotic Disorders/drug therapy; Antipsychotic Agents/pharmacology/therapeutic use; Methotrimeprazine/pharmacology/therapeutic use; Psychomotor Agitation/therapy
Description
Levomepromazine (previously known as methotrimeprazine) has a broad range of beneficial effects in the terminal phase of many illnesses, resulting from its combined antipsychotic, anxiolytic and sedative actions. Levomepromazine can safely be administered in a continuous subcutaneous infusion with most other commonly used drugs in palliative care.
1999
Rights
Article information provided for research and reference use only. PedPalASCNET does not hold any rights over the resource listed here. All rights are retained by the journal listed under publisher and/or the creator(s).
Type
Journal Article
Citation List Month
Backlog
URL Address
Citation
O'Neill J; Fountain A, “Levomepromazine (methotrimeprazine) and the last 48 hours,” Pediatric Palliative Care Library, accessed April 19, 2024, https://pedpalascnetlibrary.omeka.net/items/show/11794.